Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5345594 | 0.88 | POLB (0.56) | POLBRAB9ASMN1; SMN2NPC1CYP2C19 | |
| SCHEMBL9640983 | 0.88 | POLB (0.56) | POLBRAB9ASMN1; SMN2NPC1CYP2C19 | |
| SCHEMBL10595784 | 0.88 | POLB (0.56) | POLBRAB9ASMN1; SMN2NPC1CYP2C19 | |
| SCHEMBL6679116 | 0.87 | TACR3 (0.51) | SMN1; SMN2L3MBTL1CYP2C19 | |
| SCHEMBL6691355 | 0.85 | ALDH1A1 (0.46) | POLBSMN1; SMN2L3MBTL1CYP2C19 | |
| SCHEMBL7142421 | 0.85 | ALDH1A1 (0.46) | POLBSMN1; SMN2L3MBTL1CYP2C19 | |
| SCHEMBL31662033 | 0.85 | MEN1 (0.60) | POLBRAB9ASMN1; SMN2NPC1GRIN2B | |
| SCHEMBL8880296 | 0.85 | POLB (0.49) | POLBRAB9ASMN1; SMN2NPC1CYP2C19 | |
| SCHEMBL8880304 | 0.85 | POLB (0.49) | POLBRAB9ASMN1; SMN2NPC1CYP2C19 | |
| SCHEMBL4224751 | 0.84 | PREP (0.62) | RAB9ASMN1; SMN2NPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257544-B1 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE | VERTEX PHARMA (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20040034019-A1 | Piperazine and piperidine derivatives | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-19 | — | — | US | disclosed |
| US-20030191110-A1 | Modulators of the cholesterol biosynthetic pathway | VERTEX PHARMACEUTICALS, INCORPORATED | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034019-A1 | Piperazine and piperidine derivatives | GAP43, BDNF, NGF | POLB 1654/4885RAB9A 2932/4885SMN1; SMN2 114/4885 |
| US-20030191110-A1 | Modulators of the cholesterol biosynthetic pathway | SREBF2, SREBF1, CYP46A1 | POLB 2573/4885RAB9A 3063/4885SMN1; SMN2 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.